SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS IN ANTI-TNF-NAIVE PATIENTS AND THOSE PREVIOUSLY EXPOSED TOANTI-TNF THERAPY: 52-WEEK RESULTS FROM TWO INTERNATIONAL PHASE 3 TRIALS

被引：0
|
作者：
Deodhar, Atul [1 ]
Baeten, Dominique [2 ]
Blanco, Ricardo [3 ]
Sieper, Joachim [4 ]
Martin, Ruvie [5 ]
Porter, Brian [5 ]
Richards, Hanno [6 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Univ Amsterdam, Acad Med Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[3] Hosp Marques Valdecilla, Madrid, Spain
[4] Charite Univ Med Berlin, Berlin, Germany
[5] Novartis Pharmaceut, New York, NY USA
[6] Novartis Pharma AG, Basel, Switzerland
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2016年 / 22卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3287369
引用
收藏
页码：137 / 138
页数：2
相关论文
共 42 条
  • [31] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Efficacy and Safety Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
    Baeten, Dominique
    Braun, Jurgen
    Sieper, Joachim
    Dougados, Maxime
    Deodhar, Atul A.
    Baraliakos, Xenofon
    Porter, Brian
    Gong, Yankun
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [32] ASSOCIATION BETWEEN IMPROVEMENT IN ENTHESOPATHY AND QUALITY OF LIFE: RESULTS FROM ANTI-TNF-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS IN TWO PHASE 3 USTEKINUMAB TRIALS
    McInnes, I. B.
    Puig, L.
    Gottlieb, A. B.
    Ritchlin, C.
    You, Y.
    Song, M.
    Kafka, S.
    Tang, K. L.
    Morgan, G. J.
    Rahman, P.
    Kavanaugh, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 601 - 602
  • [33] Secukinumab 150 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial
    Marzo-Ortega, Helena
    Sieper, Joachim
    Kivitz, Alan J.
    Blanco, Ricardo
    Cohen, Martin
    Delicha, Evie Maria
    Rohrer, Susanne
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [34] SECUKINUMAB SIGNFICANTLY IMPROVES THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN PATIENTS PREVIOUSLY EXPOSED TO ANTI-TUMOUR NECROSIS FACTOR THERAPY AND ANTI-TUMOUR NECROSIS FACTOR-NAIVE PATIENTS: 52 WEEK RESULTS FROM THE PHASE III FUTURE 2 TRIAL
    McInnes, Iain
    Chinoy, Hector
    Kavanaugh, Arthur
    Wang, Zailong
    Mpofu, Shephard
    RHEUMATOLOGY, 2016, 55 : 141 - 141
  • [35] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT IN PHYSICAL FUNCTION, HEALTH-RELATED QUALITY OF LIFE, FATIGUE, AND WORK PRODUCTIVITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM AN INTERNATIONAL PHASE 3 TRIAL
    Strand, Vibeke
    Rahman, Proton
    Churchill, Melvin
    Dokoupilova, Eva
    Marzo-Orteg, Helena
    McInnes, Iain B.
    Zuazo, James
    Mpofu, Shephard
    Pricop, Luminita
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 142 - 143
  • [36] SECUKINUMAB, A MONOCLONAL ANTIBODY TO INTERLEUKIN-17A, SIGNIFICANTLY IMPROVES SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: RESULTS OF A 52-WEEK PHASE 3 RANDOMIZED PLACEBO-CONTROLLED TRIAL WITH INTRAVENOUS LOADING AND SUBCUTANEOUS MAINTENANCE DOSING
    Collins, A.
    Baeten, D.
    Braun, J.
    Baraliakos, X.
    Sieper, J.
    Dougados, M.
    Emery, P.
    Deodhar, A.
    Porter, B.
    Martin, R.
    Mpofu, S.
    Richards, H.
    INTERNAL MEDICINE JOURNAL, 2015, 45 : 41 - 41
  • [37] SECUKINUMAB SIGNIFICANTLY IMPROVES SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 52-WEEK DATA FROM MEASURE 2, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING
    Sieper, J.
    Braun, J.
    Baraliakos, X.
    Baeten, D. L.
    Dougados, M.
    Emery, P.
    Deodhar, A.
    Wei, J. C. -C.
    Porter, B.
    Andersson, M.
    Mpofu, S.
    Richards, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 132 - 133
  • [38] Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a 52-Week Phase 3 Randomized Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing.
    Baeten, Dominique L.
    Braun, Juergen
    Baraliakos, Xenofon
    Sieper, Joachim
    Dougados, Maxime
    Emery, Paul
    Deodhar, Atul A.
    Porter, Brian
    Martin, Ruvie
    Mpofu, Shephard
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S360 - S360
  • [39] BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES
    Magrey, M.
    Van de Sande, M. G. H.
    Breban, M.
    Van den Bosch, F.
    Fleurinck, C.
    Massow, U.
    De Peyrecave, N.
    Vaux, T.
    Baraliakos, X.
    Marzo-Ortega, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 876 - 877
  • [40] Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
    Magrey, Marina Nighat
    van de Sande, Marleen
    Breban, Maxime
    Van den Bosch, Filip
    Fleurinck, Carmen
    Massow, Ute
    De Peyrecave, Natasha
    Vaux, Thomas
    Baraliakos, Xenofon
    Marzo-Ortega, Helena
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1030 - 1032
12345